A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations
Endeavor Biomedicines, Inc.
Endeavor Biomedicines, Inc.
Bayer
PharmaMar
Institut Bergonié
Columbia University
National Institutes of Health Clinical Center (CC)
Labcorp Corporation of America Holdings, Inc
Intensity Therapeutics, Inc.
Cedars-Sinai Medical Center
Ipsen
Sarcoma Oncology Research Center, LLC
Rutgers, The State University of New Jersey
Stanford University
Cyteir Therapeutics, Inc.
University Hospital, Antwerp
Xencor, Inc.
Prelude Therapeutics
Cedars-Sinai Medical Center
TransThera Sciences (Nanjing), Inc.
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
Corvus Pharmaceuticals, Inc.
Deciphera Pharmaceuticals, LLC
Prelude Therapeutics
M.D. Anderson Cancer Center
Sumitomo Pharma America, Inc.
Emory University
M.D. Anderson Cancer Center
Tempest Therapeutics
Sierra Oncology LLC - a GSK company
Prelude Therapeutics
Quadriga Biosciences, Inc.
Scripps Health
Istituto Clinico Humanitas
Roswell Park Cancer Institute
Roswell Park Cancer Institute
Novartis
Amgen
Celgene
Mirror Biologics, Inc.
Swiss Cancer Institute
AEterna Zentaris
Corcept Therapeutics
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
Wake Forest University Health Sciences
Medical University of South Carolina
Dana-Farber Cancer Institute
Virginia Commonwealth University